At the news
? BEARISHIMPACT 5/10 8-K filed Sep 1, 2026 at 07:30 ET
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabling the sale of up to $100 million in common stock. This filing, combined with the prospectus supplement filed the prior day, formalizes a significant capital raise capacity for the clinical-stage biotech. The potential for substantial dilution overhangs the stock, though the company has no obligation to sell any shares.
- Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright for up to $100,000,000 in common stock.
- The agreement amends and restates the prior June 1, 2022 agreement.
- H.C. Wainwright will receive a 3.0% placement fee on shares sold as agent.
- The company filed a related prospectus supplement on August 31, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access